Publication November 5, 2026

New Publication Links SLC2A2 Variants to Glimepiride Response in GRADE Trial

On November 5, 2026, a new publication appeared in the journal Diabetes Care. The paper is titled "Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial." It was published with PubMed ID 42986362.

The publication reports on an analysis connected to the GRADE Comparative Effectiveness Clinical Trial. The title indicates the work examines common genetic variants located near the SLC2A2 gene in relation to glycemic response to glimepiride. No additional details about study design, outcomes, or conclusions were provided in the event data.

This brief reports only that the publication exists and the bibliographic details supplied. No findings, results, or interpretations from the study are described here, since none were included in the source event. Readers interested in the full content of the study should consult the journal article directly through the listed source.

Insulin glargine remains an approved medication, and this publication appears in the broader context of diabetes treatment research. For more background on insulin glargine, readers can consult the compound overview.

See the full insulin glargine overview

Source: https://pubmed.ncbi.nlm.nih.gov/42986362/